drugset
drugset / Trial / NCT03625102

A Randomized, Double-Blind Trial of Antroquinonol in Patients With Chronic Hepatitis B

NCT03625102 ↗

Phase 2 Completed 60 enrolled Golden Biotechnology Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Hepatitis B virus infection is a worldwide disease and is still the most common cause of hepatocellular carcinoma (HCC).Existing treatments for hepatitis B infection have various side-effects including renal toxicity and drug resistance or failure.

Timeline

Start
2018-08-01
Primary completion
2023-06-16
Completion
2023-06-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Antroquinonol Small molecule 50 mg Oral
Subject Antroquinonol Small molecule 100 mg Oral

Indications

chronic hepatitis B virus infection